Mixed trend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend down since Oct 2 · inside the Ichimoku cloud · RSI 43 · MACD below its signal
None of the 29 investors followed here reported a position in MDP.TO in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a MDP.TO trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 20, 2026 | Medexus Pharmaceuticals Inc.Issuer | Redemption, retraction, cancelation, repurchase at price 3.63 per share. | 1K | $3.63K |
| Aug 20, 2026 | Medexus Pharmaceuticals Inc.Issuer | — | 1K | — |
| Aug 19, 2026 | Medexus Pharmaceuticals Inc.Issuer | Redemption, retraction, cancelation, repurchase at price 3.54 per share. | 8.1K | $28.65K |
| Aug 19, 2026 | Medexus Pharmaceuticals Inc.Issuer | — | 8.1K | — |
| Aug 18, 2026 | Medexus Pharmaceuticals Inc.Issuer | Redemption, retraction, cancelation, repurchase at price 3.54 per share. | 400 | $1.42K |
| Aug 18, 2026 | Medexus Pharmaceuticals Inc.Issuer | — | 400 | — |
| Aug 9, 2026 | Medexus Pharmaceuticals Inc.Issuer | Redemption, retraction, cancelation, repurchase at price 3.53 per share. | 6.3K | $22.23K |
| Aug 9, 2026 | Medexus Pharmaceuticals Inc.Issuer | — | 6.3K | — |
| Aug 6, 2026 | Medexus Pharmaceuticals Inc.Issuer | Redemption, retraction, cancelation, repurchase at price 3.54 per share. | 3.6K | $12.74K |
| Aug 6, 2026 | Medexus Pharmaceuticals Inc.Issuer | — | 3.6K | — |
| Aug 5, 2026 | Medexus Pharmaceuticals Inc.Issuer | Redemption, retraction, cancelation, repurchase at price 3.52 per share. | 5.8K | $20.43K |
| Aug 5, 2026 | Medexus Pharmaceuticals Inc.Issuer | — | 5.8K | — |
| Aug 4, 2026 | Medexus Pharmaceuticals Inc.Issuer | Redemption, retraction, cancelation, repurchase at price 3.52 per share. | 8.2K | $28.89K |
| Aug 4, 2026 | Medexus Pharmaceuticals Inc.Issuer | — | 8.2K | — |
| Aug 3, 2026 | Medexus Pharmaceuticals Inc.Issuer | Redemption, retraction, cancelation, repurchase at price 3.51 per share. | 9.2K | $32.32K |
| Aug 3, 2026 | Medexus Pharmaceuticals Inc.Issuer | — | 9.2K | — |
| Jul 30, 2026 | Medexus Pharmaceuticals Inc.Issuer | Redemption, retraction, cancelation, repurchase at price 3.54 per share. | 10K | $35.37K |
| Jul 30, 2026 | Medexus Pharmaceuticals Inc.Issuer | — | 10K | — |
| Jul 29, 2026 | Medexus Pharmaceuticals Inc.Issuer | Redemption, retraction, cancelation, repurchase at price 3.48 per share. | 6.1K | $21.23K |
| Jul 29, 2026 | Medexus Pharmaceuticals Inc.Issuer | — | 6.1K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.7 | 1.8 | 8.3 | 26.9 | -2.0 | 31.4 | -1.6 | 4.4 | -4.6 | -3.4 | +66.0% | ||
| 2025 | 11.3 | -26.8 | -14.2 | 13.2 | 12.4 | 2.9 | -13.6 | 11.3 | -14.8 | 7.7 | -0.7 | 4.7 | −15.9% |
| 2024 | -6.1 | -23.7 | -9.0 | 13.0 | -11.0 | 12.3 | 32.4 | 1.7 | 8.2 | -10.2 | 15.5 | 25.8 | +40.1% |
| 2023 | -8.7 | -5.3 | -11.1 | -17.5 | -6.8 | 51.2 | 12.4 | 36.8 | 6.6 | -33.4 | -28.6 | 70.3 | +18.8% |
| 2022 | 12.9 | 15.3 | -5.4 | -4.5 | -30.3 | -6.2 | 19.9 | 6.0 | -61.4 | 50.0 | 56.2 | -7.6 | −18.4% |
| 2021 | 13.6 | -3.6 | 5.3 | -3.8 | -3.6 | 1.1 | -1.3 | -43.0 | -26.9 | 8.5 | -17.2 | -6.9 | −62.8% |
| 2020 | -11.4 | 14.6 | -37.5 | 18.0 | -15.3 | 48.0 | 13.5 | -6.0 | -3.0 | 12.0 | 26.6 | 26.2 | +73.9% |
| 2019 | 0.0 | -13.5 | 6.5 | -9.3 | 23.7 | -7.3 | -2.2 | -11.8 | 4.8 | -4.6 | 8.1 | -8.2 | −17.9% |
| 2018 | -5.3 | 14.8 | 3.2 | -3.1 | 3.2 | 32.8 | -8.2 | 7.7 | -20.2 | -6.0 | -1.6 | 3.2 | +12.3% |
| 2017 | 13.3 | -1.5 | -16.4 | 5.4 | 5.1 | -9.7 | 12.5 | -7.9 | 6.9 | -8.1 | 7.0 | -6.6 | −5.0% |
| 2016 | -24.5 | -7.5 | -2.7 | -11.1 | 12.5 | -8.3 | 63.6 | 11.1 | -6.7 | -12.5 | 6.1 | 15.4 | +13.2% |
| 2015 | -9.7 | -14.3 | 41.7 | 14.7 | -23.1 | 13.3 | -16.2 | -17.5 | 0.0 | 10.6 | 19.2 | -14.5 | −14.5% |
| 2014 | 0.0 | -4.4 | -34.9 | -10.7 | 16.0 | 10.3 | -17.2 | 13.2 | 3.3 | -3.2 | 3.3 | −31.1% |
Buy / hold / sell counts
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis, psoriasis, and juvenile idiopathic arthritis; Rupall, a prescription allergy medication; and GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; and intraarticular, a triamcinolone hexacetonide injectable suspension. In addition, it offers over the counter products comprising Nyda, a topical treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was founded in 2000 and is based in Toronto, Canada.
No recent headlines.